background: Low levels of plasma arachidonoylethanolamide (anandamide) (AEA) (,2 nM) are associated with a successful early pregnancy in the mouse, and are thought to be regulated by sex steroid hormones. A similar association in the human may exist, although it has never been studied. The objective of this study was to investigate plasma AEA concentrations from the time of ovulation to implantation in pregnant and non-pregnant women, and whether AEA is hormonally regulated. methods: Women who had undergone IVF/ICSI-embryo transfer were divided into pregnant (n ¼ 12) and non-pregnant (n ¼ 12) groups, based on serum b-hCG .5 IU at 4 weeks and a viable intrauterine singleton pregnancy confirmed by ultrasound at 6 weeks gestation. Blood samples for plasma AEA and sex steroid hormonal measurements were taken at the time of oocyte collection, embryo transfer and pregnancy test, and an extra sample was also taken from the pregnant group at the viability ultrasound scan.
Introduction
Infertility is an important health problem that affects 10 -15% of couples worldwide (Evers, 2002; Gnoth et al., 2005) . Although assisted reproductive technologies have overcome many infertility causes, pregnancy rates are still relatively low and have not increased in the last decade (Andersen et al., 2007) . Implantation failure is thought to be a major limiting step for the success of these techniques (Spandorfer and Rosenwaks, 1999) because it is a complex process that requires reciprocal interaction between the activated blastocyst and a receptive endometrium (Lessey, 2000; Norwitz et al., 2001; Diedrich et al., 2007) . Numerous signalling molecules have been implicated in the process of implantation (Dey et al., 2004; Dimitriadis et al., 2005) , and many of the studies have focused on the role of estradiol and progesterone, which are better understood than other molecules (Kodaman and Taylor, 2004) , although several new molecules are increasingly being identified. Anandamide is thought to be one of these novel factors involved in implantation.
Recently, studies in the mouse (Das et al., 1995; Schmid et al., 1997; Paria et al., 2002a) and sheep (Turco et al., 2008) have suggested that relatively low concentrations of anandamide are important for the implantation process. These studies have also suggested that arachidonoylethanolamide (anandamide) (AEA) signalling is involved in embryo differentiation and in improving uterine receptivity (Paria et al., 2002a) with AEA levels in-vitro being embryotoxic (Liu et al., 2002) . Such studies in humans, to the best of our knowledge, have not been undertaken. Maccarrone and co-workers have, however, suggested that plasma AEA levels during the peri-implantation stage of the menstrual cycle could well be regulated through the actions of estradiol and progesterone (Maccarrone et al., 2001; Lazzarin et al., 2004) . However, in those studies, the relationship between plasma AEA and these steroids was not examined.
Several studies have also shown that low levels of anandamide are important for early pregnancy success (Maccarrone et al., 2000 (Maccarrone et al., , 2002 Habayeb et al., 2004) and recently, a small pilot study by our group showed that a plasma AEA level of ,2 nM in pregnant women presenting with a threatened miscarriage at 6 -11 weeks gestation is predictive of pregnancy success (Habayeb et al., 2008) . Nevertheless, the exact mechanism by which AEA is either involved in early pregnancy maintenance or its levels are regulated in the human during ovulation, implantation and early pregnancy is poorly understood.
The aims of this study were, therefore, to examine plasma AEA levels at ovulation; at the implantation window and in early pregnancy; to determine whether AEA is hormonally regulated and what the exact relationship between AEA and estradiol and progesterone might be. Since quantification of AEA levels in the uterus at the time of implantation and early pregnancy in humans is ethically difficult, we used plasma AEA levels as a proxy for uterine AEA levels at the implantation window.
Materials and Methods

Subjects and treatment protocol
This was a case -control prospective study of women undergoing ovarian stimulation for infertility in an in-vitro fertilization, or intracytoplasmic sperm injection, with embryo transfer (IVF/ICSI-embryo transfer) programme. The cases were those who had a positive pregnancy test (b-human chorionic gonadotrophin (b-hCG) .5 IU/l) and ultrasound scan evidence of a viable intrauterine pregnancy and the controls were those who had a negative pregnancy test (b-hCG ,5 IU/l).
All the women studied were healthy (i.e. had no other medical disorders) and were not on any long-term medications. None of them smoked cigarettes or admitted to using any recreational drugs. The women were enrolled after getting written, signed, informed consent. The study was approved by the Leicestershire and Rutland Local Research Ethics Committee (i.e. Institutional Review Board) .
Ovarian stimulation by a long protocol using gonadotrophin hormone (GnRH) agonist (Supercur; Aventis Pharma Ltd, Kent, UK) was used to down-regulate the pituitary. This was commenced in the mid-luteal phase of the previous cycle and was administered as a daily subcutaneous injection until ovulatory hCG was given. Stimulation with subcutaneous gonadotrophins was initiated once sonographic evidence of no ovarian follicular activity and serum estradiol levels were below 200 pmol/l. The gonadotrophin was either human menopausal gonadotrophin (hMG) (Menopur; Ferring, Langley, UK) or recombinant follicle stimulating hormone (rFSH) (Puregon, Organon Laboratories Ltd, Cambridge, UK) and the dosage was based on the patient's age, BMI and early follicular phase serum FSH level. Follicular monitoring was performed by serial transvaginal ultrasound scan and serum estradiol (E2) measurements (every 2-3 days) (Lass, 2003) . The subcutaneous hCG injection (10 000 IU; Pregnyl, Organon Laboratories Ltd, Cambridge, UK) was administered to induce final oocyte maturation when there were, at least, four follicles measuring 17 mm in diameter and the endometrial thickness was at least 8 mm. Oocyte retrieval was performed 36 h later by transvaginal ultrasound-guided aspiration of the ovarian follicles.
Standard IVF/ICSI-embryo transfer procedures were followed (Braude and Rowell, 2003) . Fertilization was assessed 16 h later and the two bestquality embryos for each woman (identified by an embryologist using various morphological features) were transferred into the uterus of each patient 48 h after oocyte retrieval.
Progesterone (P4) vaginal pessaries (400 mg twice daily; Cyclogest, Shire Pharmaceuticals, Basingstoke, Hampshire, UK) were commenced after transfer of embryos to support the luteal phase until the day of pregnancy test for the non-pregnant group (control) and up to 12 weeks for the pregnant group (cases) (Nosarka et al., 2005) . Urinary pregnancy test and serum b-hCG measurements were performed 2 weeks following embryo transfer. Women with a serum b-hCG level ,5 IU/l were considered not pregnant; those with a b-hCG of .5 IU/l had a second serum b-hCG a week later and if the second b-hCG value was .1500 IU/l a transvaginal ultrasound scan was performed 4 weeks after embryo transfer (i.e. equivalent to 6 weeks gestation). The women were asked to report any vaginal bleeding or significant abdominal pain. The non-pregnant women reported vaginal bleeding, which started 1 or 2 days before the urinary b-hCG pregnancy test.
At oocyte collection, embryo transfer, urinary pregnancy tests in cases and controls and at the ultrasound scan in cases, 8 ml of blood was collected from each woman for AEA and hormonal (E2, P4, b-hCG) measurements. Samples were taken approximately 30 min before oocyte retrieval, 30 min before embryo transfer, on the day of urinary pregnancy test (4 weeks) and from the pregnant women on the day of a positive ultrasound scan (6 weeks). In a subset of seven pregnant women, extra samples for the measurement of plasma AEA were collected at Week 5 of pregnancy.
Plasma AEA measurement
Plasma AEA concentrations were estimated using our validated Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS/MS) method with lipid extraction and quantification completed within 2 h of blood sample collection (Lam et al., 2008) .
Hormone measurements
Serum estradiol (E2), progesterone (P4) and b-hCG measurements were performed on an automated ADVIA Centaur Assay System (Bayer Diagnostics, Newbury and Berkshire, UK). The inter-assay coefficients of variation for E2, P4, b-hCG were 5.6, 3.6 and 2.9%, respectively, while the intra-assay coefficients of variation were 8.4, 5.2 and 2.7%, respectively.
Statistics
A power calculation based on previous published methods for the measurement of plasma AEA (Habayeb et al., 2004 (Habayeb et al., , 2008 indicated that a minimum of six women in the pregnant and non-pregnant groups would allow a clinically significant difference of 40% in plasma AEA concentrations to be observed with 80% power, assuming two-sided a ¼ 0.05. Statistical analysis of the data was performed using one-way ANOVA with Tukey's honestly significance difference test and comparison between groups was performed using the Student's unpaired t-test; P , 0.05 was considered significant. Data relating to patient demographics and cycle characteristics are presented as mean + SD (with the range) or as median where appropriate. Plasma AEA and serum E2, P4 and b-hCG measurements are presented as mean + SEM. Linear regression analysis was used to determine the associations between plasma AEA and serum E2, P4, b-hCG. Data were analysed using InStat Version 3.01 (GraphPad Software Inc., San Diego, CA, USA; www.graphpad.com).
Results
Subjects and cycle characteristics of the study groups
In total, 24 infertile women were recruited into the study; 12 pregnant (pregnant group) and 12 non-pregnant (non-pregnant group). They were matched for age, BMI, duration of infertility, type of infertility (primary, secondary), cause of infertility and basal FSH and LH levels, as shown in Table I .
These women were from a cohort of 78 women undergoing IVF/ ICSI-embryo transfer. Once a pregnant case was identified, the next non-pregnant case who was matched for age, BMI, duration, type and cause of infertility was selected as control. The treatment protocols in the two groups of women were very similar (Table II) . There was, however, a significantly higher number of ovarian stimulation days for the non-pregnant when compared with the pregnant group (P ¼ 0.01). Despite the fertilization rates not being significantly different in both groups (P ¼ 0.11), the pregnant women produced approximately double the number of embryos for transfer compared with the non-pregnant women (P ¼ 0.01). In addition, the total number of good quality embryos available on the day of embryo transfer was significantly higher in the pregnant group (P ¼ 0.003).
Plasma AEA levels
In the pregnant women, the highest plasma AEA levels (mean + SEM) were observed at the time of oocyte retrieval (1.16 + 0.15 nM) and the pregnancy test (1.18 + 0.09 nM) ( Table III ). The lowest measurable plasma AEA levels were from samples taken just prior to embryo transfer and on the day of a positive ultrasound scan (0.66 + 0.04 and 0.67 + 0.06 nM, respectively) (Table III) . In the pregnant group, plasma AEA levels decreased significantly (P , 0.001) from the day of oocyte retrieval to the day of embryo transfer with a mean fall of 43.2%. However, AEA levels rose significantly (P , 0.001) from the day of embryo transfer to that of pregnancy test followed by another significant (P , 0.001) decrease from the time of pregnancy test to the first ultrasound scan ( Fig. 1 ; Table III ).
The changes in plasma AEA levels from embryo transfer to 6 weeks gestation (4 weeks after embryo transfer) in the seven pregnant women who had an additional blood sample taken at 5 weeks are shown in Table IV and Fig. 2 . There was a significant (P ¼ 0.006) increase in plasma AEA level from the day of embryo transfer (i.e. Week 2 gestation) (0.67 + 0.06 nM) to that (1.17 + 0.14 nM) at Week 4 gestation. There was no significant (P ¼ 0.97) change in plasma AEA levels at Week 4 to that at Week 5 (1.18 + 0.13 nM), but there was a significant decrease (P , 0.05) from Week 4 (1.17 + 0.14 nM) to Week 6 (0.66 + 0.06 nM). A similar significant decrease was seen from the levels at 5 weeks to that at 6 weeks gestation (P ¼ 0.003).
In contrast, in the non-pregnant group, the highest plasma AEA levels (1.31 + 0.14 nM) were seen on the day of the pregnancy test and the lowest levels were on the day of oocyte retrieval (0.89 + 0.07 nM) and on the day of embryo transfer (0.71 + 0.08 nM). Unlike the significant changes seen in plasma levels of the pregnant women from the day of the oocyte retrieval to the day of embryo transfer, there was no statistically significant difference in plasma AEA levels between oocyte retrieval and embryo transfer in non-pregnant group. The mean difference in the decline in plasma AEA levels between the two periods was only 20.2%. There was a significant increase in plasma AEA levels from the day of oocyte retrieval to the day of pregnancy test (P , 0.05) and a significant increase from the day of embryo transfer to the day of pregnancy test (P , 0.0001).
An analysis of plasma AEA levels between the pregnant and nonpregnant groups at the three studied time periods showed that Plasma AEA, sex steroid hormones and IVF-embryo transfer there was no statistically significant difference between the two groups of women (Table III) .
Serum E2, P4 and b-hCG levels
The highest level (9689 + 1935 pmol/l) of serum E2 in the pregnant women was on the day of ultrasound scan and the lowest (4324 + 635 pmol/l) on the day of embryo transfer ( Fig. 1) . Although there appeared to be a subtle fluctuation in the serum E2 concentrations over the course of treatment, these data were not significantly different. For the non-pregnant group, the highest level (4295 + 622.8 pmol/l) of serum E2 was noted on the day of oocyte retrieval and the lowest level (129.6 + 21.7 pmol/l) on the day of the negative pregnancy test (Fig. 1) . The decrease in serum E2 concentrations observed from the day of oocyte retrieval to the day of pregnancy test in the non-pregnant group was significant (P , 0.0001). A similar decrease in serum E2 concentrations from 3534 + 616.5 pmol/l on the day of embryo transfer to 129.6 + 21.7 pmol/l on the day of pregnancy test was also significantly different (P , 0.0001). When the serum E2 levels in the pregnant and nonpregnant groups were compared (Table III) , only the levels on the day of pregnancy test were significantly different (P ¼ 0.002). Serum P4 levels in the pregnant group were highest (483.7 + 123 nmol/l) on the day of positive pregnancy test and on the day of ultrasound scan (471.7 + 99.3 nmol/l) (Fig. 1) . The P4 level was lowest (49.6 + 11.2 nmol/l) on the day of oocyte retrieval and then increased significantly (P , 0.0001) on the day of embryo transfer (364.9 + 64.1 nmol/l). The serum P4 levels on the day of embryo transfer, pregnancy test and ultrasound scan were not significantly different (Fig. 1) . In the non-pregnant group, the highest P4 level (241.8 + 39.4 nmol/l) was observed on the day of embryo transfer and the lowest (32.2 + 4.8 nmol/l) was on the day of oocyte retrieval. There was a significant (P , 0.0001) increase in serum P4 levels from that on the day of oocyte retrieval to that on the day of embryo transfer, and a significant decrease to that (42.1 + 8.5 nmol/l) on the day of negative pregnancy test (P , 0.0001). A comparison between the serum P4 levels in the pregnant and nonpregnant groups (Table III) showed that only the levels found on the day of pregnancy test were significantly different (P ¼ 0.002).
Serum b-hCG levels measured exactly 2 weeks after embryo transfer were significantly higher in the pregnant group (202.5 + 29.59 IU/l; range 70 -392 IU/l) than in the non-pregnant group (all were ,2 IU/l).
Hormonal associations
The possible relationships between plasma AEA levels and serum levels of the sex steroids (E2, P4) in the pregnant and non-pregnant groups at oocyte retrieval, embryo transfer and pregnancy test were examined. These data are shown in Table V . There was no significant correlation in the pregnant and non-pregnant groups between plasma AEA levels and serum P4 levels (R 2 ¼ 0. between plasma AEA levels and serum E2 levels (R 2 ¼ 0.002; P ¼ 0.17), plasma AEA levels and serum P4 levels (R 2 ¼ 0.753; P ¼ 0.010) and plasma AEA levels and serum b-hCG levels (R 2 ¼ 0.031;
Discussion
Embryo quality (Bergh and Novat, 1992) and an appropriately hormonally primed receptive endometrium (Norwitz et al., 2001 ; Diedrich The stages are: OR, oocyte retrieval; PT, pregnancy test; USS, first positive ultrasound scan; AEA, anandamide; E2, estradiol; P4, progesterone. Data are presented as mean + SEM; *P , 0.05; **P , 0.0001 one-way ANOVA, with Tukey's honestly significant differences test.
et al., 2007) are considered to be important factors for successful implantation. A third recognized ingredient in successful implantation is successful cross-talk between the embryo and the primed receptive endometrium (Paria et al., 2002b; Dey et al., 2004) . A current lack of understanding of the molecules that regulate this process (Dimitriadis et al., 2005) means that implantation failure remains a major obstacle to improving pregnancy outcomes following fertilization. It can be implied from animal studies demonstrating that AEA is involved in implantation (Das et al., 1995) that a similar process occurs in women. Examining women during their treatment in an IVF-embryo transfer programme provided an opportunity to accurately study the relationship between plasma AEA and the steroids E2 and P4 at the time of ovulation, the implantation window and early pregnancy. In addition, it allowed for the comparison of plasma AEA levels in a cohort of women who had a positive implantation as evidenced by a viable pregnancy at 6 weeks gestation and another cohort who failed to implant.
An important finding in this study was the statistically significant reduction (43%) in plasma AEA levels in the pregnant group, but not in the non-pregnant group, that occurred during the transition from the day of oocyte retrieval to the day of embryo transfer. If the plasma AEA levels reflect those in the uterus, then this observation would be in keeping with the findings of Guo et al. (2005) that the levels of AEA in the uterine cavity fall to enable successful implantation.
The changes in plasma AEA levels from the day of embryo transfer to 6 weeks gestation revealed that in a viable pregnancy, a low AEA level was required on the day of embryo transfer and a higher level was required at 4 and 5 weeks gestation, only significantly falling thereafter. AEA levels at the sixth week of pregnancy were similar to the previously reported levels in early pregnancy (Maccarrone et al., 2000; Habayeb et al., 2008) and none of our pregnant women had AEA values .2 nM at 6 weeks and since none had miscarried by 12 weeks, this finding was in keeping with previous observations (Maccarrone et al., 2000; Habayeb et al., 2008) .
Our findings suggest that plasma AEA levels fluctuate between ovulation and very early pregnancy and that for successful pregnancy to occur, a higher plasma AEA level is probably required at the time of ovulation and a significantly lower level is required at the beginning of implantation to assist in uterine receptivity. At the start of implantation, an interaction between the embryo and endometrium occurs and higher AEA levels are probably then required or the levels increase due to the development of the trophoblast. Our assumption The table shows plasma AEA measurements at embryo transfer (AEA-embryo transfer), at 4 weeks (AEA-1) at 5 weeks (AEA-2) and at 6 weeks (AEA-USS). Serum b-hCG at 4 weeks (b-hCG1) and 5 weeks (b-hCG2) gestation are shown. USS, the date of transvaginal scan (weeks þdays ); AEA, AEA concentration; b-hCG, serum b-hCG concentrations; nd, not determined because b-hCG1 was sufficiently high enough to indicate the pregnancy was progressing.
Figure 2 Plasma AEA levels in pregnant women at 2, 4, 5 and 6 weeks gestation. The data are presented as individual values (n ¼ 7) with the mean as the long horizontal bar and the SEM as the shorter horizontal bars. P-values shown above the data were calculated using one-way ANOVA, with Tukey's honestly significant differences test.
Plasma AEA, sex steroid hormones and IVF-embryo transfer that plasma AEA levels change at various stages during the human implantation process, as reported in mouse (Sun and Dey, 2008) , is currently difficult to confirm, because there is no evidence that AEA is produced by either the human uterus or embryo. Additionally, there is no evidence that the plasma AEA levels reflect the changes in uterine AEA levels. Whilst we are making an assumption that plasma AEA levels are proxy to uterine levels, further studies will be required to investigate this assumption.
With regards to the regulation of plasma AEA, our data and the well-recognized physiological levels of hormones controlling the periods studied (Dodson et al., 1975) provide clues to possible mechanisms regulating AEA levels. We observed no statistically significant relationship between plasma AEA and P4 at implantation and during early pregnancy, suggesting that there is no significant association between plasma AEA and P4. Previous studies have suggested that progesterone down-regulates AEA levels during the implantation window. Since both the pregnant and non-pregnant groups in this study had similar high levels of progesterone on the day of embryo transfer, prior to starting the extra progesterone supplement to support their luteal phase, a similar low plasma AEA level in both groups would have been expected. The data, however, showed that the pregnant group had high P4 and high AEA levels, and the nonpregnant group had low P4 levels and high plasma AEA levels, suggesting that P4 is not the controlling factor in these two groups of women. Furthermore, the lack of correlation between the plasma AEA levels and serum P4 at 6 weeks gestation also supported this conclusion. These data are qualitatively similar to our previous study of normal cycling women (El-Talatini et al., 2009) where no association between AEA and P4 was found. Thus we can conclude that AEA in women is most probably not regulated by P4.
Since oocyte retrieval can be assumed to correspond to the ovulation stage in the natural cycle, embryo transfer equivalent to the implantation window or mid-luteal phase of the natural cycle, and a negative pregnancy test equivalent to the early follicular phase of the next cycle (these women started bleeding due to the withdrawal of their progesterone levels), it is reasonable to conclude that the changes in plasma AEA levels correlate with well-documented physiological changes in gonadotrophin levels (Duncan et al., 1996) . It is well known that hCG can mimic the action of LH (Speroff and Fritz, 2005) in the corpus luteum. Indeed, hCG injection is given to all these women 36 h before oocyte retrieval to induce ovulation (Fischer et al., 1993) , mimicking the LH surge. However, in pregnant women, at the time of a positive pregnancy test, physiologically, LH levels and hCG levels are elevated (Duncan et al., 1996) .
The hCG secreted from the syncytiotrophoblast 1 day after implantation and the LH secreted from maternal anterior pituitary both support the corpus luteum in its role of producing steroids that are important for pregnancy survival, leading to elevated P4 and E2 levels. The corpus luteum is totally dependent on hCG levels until the seventh week of pregnancy (Baird et al., 2003) and from then to the 10th week of pregnancy, the function of the corpus luteum is gradually replaced by placenta (Speroff and Fritz, 2005 ). Since we have concluded that AEA may be regulated by gonadotrophins in nonpregnant women, it is not surprising that AEA levels in pregnant women were also elevated at 4 and 5 weeks gestation as LH levels are elevated. However, at the sixth week of pregnancy, even though hCG levels remain high, the LH receptors in the corpus luteum are gradually declining and the corpus luteum is starting to regress as the placenta begins to produce all the hormones that support the pregnancy (Speroff and Fritz, 2005 The R 2 and P-values are shown with significant associations in bold. nd ¼ not determined because the women were not pregnant.
become very low and the levels of AEA accordingly decline supporting the observation that plasma AEA levels decline further after the sixth week of gestation. The fact that we found no relationship between plasma AEA and serum b-hCG, which is exclusively produced from trophoblast, is in keeping with the findings of Maccarrone et al. (2002) , suggesting that AEA during the early weeks of pregnancy is mainly regulated by maternal LH.
All of these data are consistent with the notion that during the follicular phase of the menstrual cycle, FSH is the main controlling factor regulating plasma AEA levels, whereas during ovulation, implantation and early pregnancy, AEA is regulated by LH and E2.
In summary, our results suggest that in a viable pregnancy, AEA levels fluctuate from the time of ovulation to early pregnancy, with the highest levels being at the time of ovulation and the lowest at 6 weeks gestation. A significant decline in the plasma AEA levels (around 40%) at the implantation window is important. Additionally, the changes in plasma AEA levels from oocyte retrieval to embryo replacement (implantation window) could possibly be of use to predict the cases in which implantation will be successful in women undergoing IVF/ICSI-embryo transfer. Larger studies are however, essential to confirm this observation.
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